Final Data Likely Soon in Phase 2 Trial of Temelimab for Relapsing MS
A Phase 2 clinical trial into the safety and tolerability of higher-doseĀ temelimab as a potential therapy for relapsing forms of multiple sclerosis (MS) is now complete, and top-line data is expected by late March, its developer,Ā GeNeuro, announced. The ProTEct-MS Phase 2 trial (NCT04480307), conducted at the Karolinska…